Summary
The AI statements largely describe oral calcium acetate for chronic kidney disease/hyperphosphatemia and coupon/assistance programs. The provided FDA label excerpt is for Calcium Gluconate in Sodium Chloride Injection for acute symptomatic hypocalcemia, and the AI response makes multiple unsupported and potentially misleading off-label/incorrect product claims relative to the supplied labeling.
Category Scores
Accurate Statements
No accurately supported statements were identified against the supplied FDA label excerpts.
The provided label excerpts do not discuss calcium acetate, coupons/PAPs, chronic kidney disease/hyperphosphatemia, or administration/side effects for calcium acetate.
Unsupported Statements
Calcium acetate is prescribed to manage hyperphosphatemia in patients with chronic kidney disease.
The supplied label excerpt is for Calcium Gluconate in Sodium Chloride Injection indicated for acute symptomatic hypocalcemia; it does not mention calcium acetate or hyperphosphatemia/CKD.
Patient assistance programs and discount coupons for calcium acetate aim to reduce out-of-pocket costs.
Not supported by the supplied prescribing information excerpts (none address patient assistance or discount coupons).
Manufacturer patient assistance programs (PAPs) for calcium acetate can offer significant savings or even free medication to eligible patients who meet certain income requirements and lack adequate prescription drug coverage.
Not supported by the supplied prescribing information excerpts (none address PAP eligibility terms or availability).
Calcium acetate coupons function as a discount at the point of sale at participating pharmacies.
Not supported by the supplied prescribing information excerpts.
When a valid calcium acetate coupon is presented at a participating pharmacy, the price of the prescription is reduced.
Not supported by the supplied prescribing information excerpts.
Calcium acetate coupons may have terms and conditions such as expiration dates and limitations on who can use them (e.g., not valid for government-insured patients).
Not supported by the supplied prescribing information excerpts.
Without insurance, the cost of calcium acetate can be substantial.
Not supported by the supplied prescribing information excerpts (pricing/cost statements are absent).
Calcium acetate is a generic medication whose original patents have long expired.
Not supported by the supplied prescribing information excerpts.
Generic versions of calcium acetate can be produced and marketed by multiple manufacturers, contributing to general availability and more competitive pricing.
Not supported by the supplied prescribing information excerpts.
Calcium acetate is used to control high phosphorus levels (hyperphosphatemia) in people with chronic kidney disease who are on dialysis.
Not supported by the supplied label excerpt (which is for acute symptomatic hypocalcemia with Calcium Gluconate in Sodium Chloride Injection).
Calcium acetate binds to phosphate in the gastrointestinal tract to prevent absorption of excess phosphorus.
Not supported by the supplied label excerpt (mechanism of action provided in the excerpt is for intravenous calcium gluconate increasing serum ionized calcium).
Calcium acetate helps maintain calcium and phosphorus balance in the body.
Not supported by the supplied label excerpt.
Common side effects of calcium acetate can include constipation, nausea, and vomiting.
Not supported by the supplied label excerpt (the excerpted adverse reactions are for Calcium Gluconate in Sodium Chloride Injection and do not mention these gastrointestinal side effects for calcium acetate).
More serious side effects of calcium acetate may involve hypercalcemia (high blood calcium levels).
The label excerpt for Calcium Gluconate in Sodium Chloride Injection indicates hypercalcemia may result from overdosage, but the statement is about calcium acetate specifically; it is unsupported as written for calcium acetate.
Hypercalcemia from calcium acetate can lead to symptoms such as drowsiness, confusion, and irregular heartbeat.
Not supported by the supplied label excerpt.
Other phosphate binders available for managing hyperphosphatemia include sevelamer carbonate, lanthanum carbonate, and ferric citrate.
Not supported by the supplied prescribing information excerpts.
Calcium acetate alternatives (sevelamer carbonate, lanthanum carbonate, and ferric citrate) may also have coupon and patient assistance program offerings.
Not supported by the supplied prescribing information excerpts.
Contradictions
Low
AI Statement
Calcium acetate is prescribed to manage hyperphosphatemia in patients with chronic kidney disease.
Label Reference
Provided label excerpt: “Calcium Gluconate in Sodium Chloride Injection is indicated… for the treatment of acute symptomatic hypocalcemia.”
Low
AI Statement
Calcium acetate is used to control high phosphorus levels (hyperphosphatemia) in people with chronic kidney disease who are on dialysis.
Label Reference
Provided label excerpt: indication is acute symptomatic hypocalcemia; no dialysis/hyperphosphatemia indication provided.
Important Omissions
The response did not include the FDA-labeled indication for Calcium Gluconate in Sodium Chloride Injection (acute symptomatic hypocalcemia) and instead discussed calcium acetate/hyperphosphatemia.
Importance:
High
The response did not include key FDA-labeled administration instructions (e.g., do not dilute prior to use; inspect for particulate/discoloration; IV infusion/monitoring; avoid rapid injection rates) that are central to the provided label.
Importance:
High
The response did not include FDA-labeled contraindications and major warnings relevant to Calcium Gluconate in Sodium Chloride Injection (hypercalcemia; neonatal ceftriaxone contraindication; ceftriaxone-calcium precipitates; tissue necrosis/calcinosis; aluminum toxicity; infusion-related hypotension/bradycardia/arrhythmias).
Importance:
High
Safety Assessment
Potential Patient Risk:
High
The response focuses on calcium acetate for CKD-related hyperphosphatemia and on coupon/PAP/pricing topics, which are not supported by the provided FDA label excerpts for Calcium Gluconate in Sodium Chloride Injection. It omits multiple high-relevance label safety/administration elements (contraindications, serious warnings, monitoring, and infusion guidance), creating a material risk of misinformation if used clinically.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major mismatch between the provided FDA label (Calcium Gluconate in Sodium Chloride Injection for acute symptomatic hypocalcemia) and the AI claims (Calcium acetate for CKD hyperphosphatemia) plus omission of critical labeled contraindications/warnings/administration/monitoring.
Suggested Improvement
Limit claims strictly to the provided FDA label excerpt for Calcium Gluconate in Sodium Chloride Injection (indications, contraindications, administration/infusion rate and monitoring, drug incompatibilities such as ceftriaxone/Y-site and mixing restrictions, and labeled serious adverse reactions/warnings). Do not introduce calcium acetate-specific mechanisms/side effects or coupon/PAP/pricing assertions unless supported in the provided label text.